Ergomed proposes acquisition of Haemostatix
5 May 2016 | By Victoria White, Digital Content Producer
Ergomed is acquiring 100% of the issued share capital of Haemostatix for an initial consideration of £8.0 million...
List view / Grid view
News
Quotient Clinical and Upperton announce a spray drying partnership to deliver integrated formulation development and GMP manufacturing programs for poorly soluble drugs
4 May 2016 | By Quotient Clinical
Quotient Clinical and Upperton have announced a partnership to address drug delivery challenges...
VAXIMM AG begins journey to single arm study of VXM01 therapy
The Swiss-German biotech company, VAXIMM AG, has announced the enrolment of its first patient in a Phase 2a clinical trial for immunotherapy, VXM01.
NICE allows extra time for agreement on ataluren price
4 May 2016 | By Victoria White, Digital Content Producer
NICE has allowed extra time for further discussions on access arrangements for PTC Therapeutics’ Translarna (ataluren) for Duchenne Muscular Dystrophy...
FDA grants Priority Review for olaratumab BLA
4 May 2016 | By Victoria White, Digital Content Producer
The US Food and Drug Administration (FDA) has granted Priority Review to Lilly’s biologics license application (BLA) for olaratumab, in combination with doxorubicin, for the potential treatment of people with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery.
Heart failure treatment market to rise to $11.8 billion
4 May 2016 | By Victoria White, Digital Content Producer
The heart failure treatment market is set to rise from around $3.2 billion in 2015 to $11.8 billion by 2025, according to research and consulting firm GlobalData.
Chinese companies increase services in finished dosage, exports and bio services at CPhI China 2016
4 May 2016 | By CPhI
CPhI China returns to the Shanghai New International Exhibition Centre (SNIEC) China from 21st to 23rd June 2016...
Positive top line results from ALX-0171 infant RSV study
4 May 2016 | By Victoria White, Digital Content Producer
The study met its primary endpoint, demonstrating the favourable safety and tolerability profile of ALX-0171 when administered daily by inhalation...
Biogen announces plans to spin off its haemophilia business
3 May 2016 | By Victoria White, Digital Content Producer
The new company, to be named at a later date, will focus on the discovery and development of therapies for the treatment of haemophilia...
Pall Life Sciences Launches Commercial Cadence Acoustic Separator for Intensified Bioprocess Clarification and Purification Applications
3 May 2016 | By Pall Life Sciences
The Cadence Acoustic Separator applies acoustic wave separation technology in a single-use format for the clarification of cell culture bioprocess fluids...
Janssen’s IMBRUVICA® receives recommendation to broaden treatment application for CLL patients
3 May 2016 | By Mandy Parrett, Editorial Assistant
Janssen-Cilag International NV have reported that their therapy IMBRUVICA® (ibrutinib) has received a ‘Positive Opinion’ from the CHMP recommending that its use be extended for CLL patients.
EC grants orphan designation to pSivida’s Medidur
3 May 2016 | By Victoria White, Digital Content Producer
The EC has granted orphan medicinal product designation to Medidur for the treatment of chronic non-infectious uveitis of the posterior of the eye...
FDA approves Nuplazid to treat hallucinations in Parkinson’s disease
3 May 2016 | By Victoria White, Digital Content Producer
The FDA has approved Acadia’s Nuplazid, the first drug approved to treat hallucinations and delusions experienced by some people with Parkinson’s disease...
Medivation’s Board rejects Sanofi’s unsolicited proposal
3 May 2016 | By Victoria White, Digital Content Producer
Medivation’s Board has determined that the proposal from Sanofi to acquire Medivation for $52.50 per share substantially undervalues the company...
NICE recommends trametinib plus dabrafenib in melanoma
3 May 2016 | By Victoria White, Digital Content Producer
NICE has published final draft guidance recommending trametinib in combination with dabrafenib to treat some patients with melanoma...
